China NMPA Drug Inspection - 17 companies including Hebei Kangyiqiang Pharmaceutical Co., Ltd. - 19 batches of Chinese herbal medicine pieces

The Shandong Provincial Food and Drug Administration, operating within China's national regulatory framework, issued an announcement on October 10, 2018, detailing significant quality control failures. Following inspections by nine drug testing institutions, a total of 20 drug batches were identified as substandard. Specifically, one batch from Jiangsu Dahongying Hengshun Pharmaceutical Co., Ltd. failed quality inspection, along with 19 batches of traditional Chinese medicine decoction pieces produced by 17 other companies, including Hebei Kangyiqiang Pharmaceutical Co., Ltd. In response to these findings, municipal food and drug administrations initiated immediate regulatory actions. These included sealing, seizing, suspending sales, and recalling the non-compliant products to prevent further distribution. Investigations have been launched or are ongoing into the responsible manufacturers and sampled units to ascertain the root causes of the quality deviations and ensure compliance with pertinent laws and regulations. The Administration further instructed municipal authorities to intensify oversight of the affected enterprises, requiring them to thoroughly investigate the issues, implement comprehensive rectification measures, and effectively address and eliminate any potential product risks. This comprehensive approach aims to uphold drug quality and public safety.